Table 1.
Association between FSTL1 expression and clinicopathological features of GC in Zhejiang cohort 3
| No. patients | Low expression (n = 53) | High expression (n = 53) | P value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 83 (78.3%) | 41 (38.7%) | 42 (39.6%) | 0.8137a |
| Female | 23 (21.7%) | 12 (11.3%) | 11 (10.4%) | |
| Age | ||||
| ≤ 60 | 44 (41.5%) | 20 (18.9%) | 24 (22.6%) | 0.4304a |
| > 60 | 62 (58.5%) | 33 (31.1%) | 29 (27.4%) | |
| Grade | ||||
| G1-2 | 9 (8.5%) | 6 (5.7%) | 3 (2.8%) | 0.4895b |
| G3 | 97 (91.5%) | 47 (44.3%) | 50 (47.2%) | |
| T stage | ||||
| T1-2 | 15 (14.2%) | 12 (11.3%) | 3 (2.8%) | 0.0258b |
| T3-4 | 91 (85.8%) | 41 (38.7%) | 50 (47.2%) | |
| N stage | ||||
| N0 | 21 (19.8%) | 15 (14.1%) | 6 (5.7%) | 0.0283a |
| N1-3 | 85 (80.2%) | 38 (35.8%) | 47 (44.3%) | |
| M stage | ||||
| M0 | 89 (84%) | 48 (45.2%) | 41 (38.7%) | 0.0639a |
| M1 | 17 (16%) | 5 (4.7%) | 12 (11.3%) | |
| Tumor size | ||||
| ≤ 5 cm | 60 (56.6%) | 34 (32.1%) | 26 (24.5%) | 0.1169a |
| > 5 cm | 46 (43.4%) | 19 (17.9%) | 27 (25.5%) | |
| AJCC stage | ||||
| I-II | 30 (28.3%) | 20 (18.9%) | 10 (9.4%) | 0.0311a |
| III-IV | 76 (71.7%) | 33 (31.1%) | 43 (40.6%) |
a
Chi-square test;
b
Yates’ continuity corrected chi-square test.